-
Eli Lilly released new data from a study of its obesity drug Tirzepatide
On October 3, Eli Lilly presented the latest research data on Tirzepatide at the 59th Annual meeting of the European Association for the Study of Diabetes (EASD). The results showed that Tirzepatide ( ... -
The magic medicine for weight loss has become popular: Novo Nordisk shows the indication literature Lilly shows the association between diabetes and obesity
The 6th CIIE has arrived as scheduled, and this year's medical device and healthcare exhibition area has also attracted the participation of global multinational pharmaceutical giants. -
Smegglutide has been approved for the treatment of obesity in China, with a supply chain gap of over 70 billion US dollars in the market
June 25th. Novo Nordisk announced that the National Medical Products Administration has approved its research and production of Novo Nordisk; reg; The marketing application of Smegglutide Injection f ... -
Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
On June 25th, the National Medical Products Administration (NMPA) approved the marketing application of Novo Nordisk's Novo Nordisk developed and produced Novo Nordisk's Novo Nordisk Injection (for l ...